On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug
On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.